Cargando…

Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis

Lipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use in a rapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantera, Jason L., Lillis, Lorraine M., Peck, Roger B., Moreau, Emmanuel, Schouten, James A., Davis, Paul, Drain, Paul K., Andama, Alfred, Pinter, Abraham, Kawasaki, Masanori, Källenius, Gunilla, Sundling, Christopher, Dobos, Karen M., Flores, Danara, Chatterjee, Delphi, Murphy, Eileen, Halas, Olivia R., Boyle, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524686/
https://www.ncbi.nlm.nih.gov/pubmed/36178936
http://dx.doi.org/10.1371/journal.pone.0274415
_version_ 1784800548145332224
author Cantera, Jason L.
Lillis, Lorraine M.
Peck, Roger B.
Moreau, Emmanuel
Schouten, James A.
Davis, Paul
Drain, Paul K.
Andama, Alfred
Pinter, Abraham
Kawasaki, Masanori
Källenius, Gunilla
Sundling, Christopher
Dobos, Karen M.
Flores, Danara
Chatterjee, Delphi
Murphy, Eileen
Halas, Olivia R.
Boyle, David S.
author_facet Cantera, Jason L.
Lillis, Lorraine M.
Peck, Roger B.
Moreau, Emmanuel
Schouten, James A.
Davis, Paul
Drain, Paul K.
Andama, Alfred
Pinter, Abraham
Kawasaki, Masanori
Källenius, Gunilla
Sundling, Christopher
Dobos, Karen M.
Flores, Danara
Chatterjee, Delphi
Murphy, Eileen
Halas, Olivia R.
Boyle, David S.
author_sort Cantera, Jason L.
collection PubMed
description Lipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use in a rapid diagnostic test (RDT). We evaluated the analytical performance of the TB LAM Igs to identify pairs that offer superior performance over existing urine LAM tests. We assessed 25 new and 4 existing Igs in a matrixed format using a multiplex electrochemiluminescence-based liquid immunoassay. A total of 841 paired Ig combinations were challenged with in vitro cultured LAM (cLAM) derived from MTB strains representing diverse phylogenetic lineages, alongside urinary LAM (uLAM) from the urine of adults with active pulmonary TB. Analytical sensitivity of down-selected Ig pairs was determined using MTB Aoyama-B cLAM, while diagnostic accuracy was determined using clinical samples. When testing cLAM, the reactivity of Ig pairs was similar across MTB lineages 1–4 but lineage 5:6 had significantly more reactivity among Ig pairs. Overall, 41 Ig pairs had a strong binding affinity to cLAM, as compared to the reference pair of S4-20/A194-01, and 28 Ig pairs therein exhibited a strong affinity for both cLAM and uLAM. Retrospective testing on clinical urine specimens demonstrated varying sensitivities (12–80%) and specificities (14–100%). The five top pairs had a similar analytical limit of detection to the reference pair but in four instances, the sensitivity and specificity with clinical uLAM samples was poor. Overall, epitopes presented by uLAM are different from cLAM, which may affect antibody performance when testing uLAM in patient samples. Several new Ig pairs had similar ranges of high sensitivity to cLAM but overall, there were no new candidate Ig pairs identified in this round of screening with increased performance with uLAM as compared to an existing optimal pair.
format Online
Article
Text
id pubmed-9524686
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-95246862022-10-01 Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis Cantera, Jason L. Lillis, Lorraine M. Peck, Roger B. Moreau, Emmanuel Schouten, James A. Davis, Paul Drain, Paul K. Andama, Alfred Pinter, Abraham Kawasaki, Masanori Källenius, Gunilla Sundling, Christopher Dobos, Karen M. Flores, Danara Chatterjee, Delphi Murphy, Eileen Halas, Olivia R. Boyle, David S. PLoS One Research Article Lipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use in a rapid diagnostic test (RDT). We evaluated the analytical performance of the TB LAM Igs to identify pairs that offer superior performance over existing urine LAM tests. We assessed 25 new and 4 existing Igs in a matrixed format using a multiplex electrochemiluminescence-based liquid immunoassay. A total of 841 paired Ig combinations were challenged with in vitro cultured LAM (cLAM) derived from MTB strains representing diverse phylogenetic lineages, alongside urinary LAM (uLAM) from the urine of adults with active pulmonary TB. Analytical sensitivity of down-selected Ig pairs was determined using MTB Aoyama-B cLAM, while diagnostic accuracy was determined using clinical samples. When testing cLAM, the reactivity of Ig pairs was similar across MTB lineages 1–4 but lineage 5:6 had significantly more reactivity among Ig pairs. Overall, 41 Ig pairs had a strong binding affinity to cLAM, as compared to the reference pair of S4-20/A194-01, and 28 Ig pairs therein exhibited a strong affinity for both cLAM and uLAM. Retrospective testing on clinical urine specimens demonstrated varying sensitivities (12–80%) and specificities (14–100%). The five top pairs had a similar analytical limit of detection to the reference pair but in four instances, the sensitivity and specificity with clinical uLAM samples was poor. Overall, epitopes presented by uLAM are different from cLAM, which may affect antibody performance when testing uLAM in patient samples. Several new Ig pairs had similar ranges of high sensitivity to cLAM but overall, there were no new candidate Ig pairs identified in this round of screening with increased performance with uLAM as compared to an existing optimal pair. Public Library of Science 2022-09-30 /pmc/articles/PMC9524686/ /pubmed/36178936 http://dx.doi.org/10.1371/journal.pone.0274415 Text en © 2022 Cantera et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cantera, Jason L.
Lillis, Lorraine M.
Peck, Roger B.
Moreau, Emmanuel
Schouten, James A.
Davis, Paul
Drain, Paul K.
Andama, Alfred
Pinter, Abraham
Kawasaki, Masanori
Källenius, Gunilla
Sundling, Christopher
Dobos, Karen M.
Flores, Danara
Chatterjee, Delphi
Murphy, Eileen
Halas, Olivia R.
Boyle, David S.
Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis
title Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis
title_full Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis
title_fullStr Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis
title_full_unstemmed Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis
title_short Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis
title_sort performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for mycobacterium tuberculosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524686/
https://www.ncbi.nlm.nih.gov/pubmed/36178936
http://dx.doi.org/10.1371/journal.pone.0274415
work_keys_str_mv AT canterajasonl performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT lillislorrainem performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT peckrogerb performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT moreauemmanuel performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT schoutenjamesa performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT davispaul performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT drainpaulk performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT andamaalfred performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT pinterabraham performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT kawasakimasanori performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT kalleniusgunilla performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT sundlingchristopher performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT doboskarenm performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT floresdanara performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT chatterjeedelphi performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT murphyeileen performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT halasoliviar performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis
AT boyledavids performanceofnovelantibodiesforlipoarabinomannantodevelopdiagnostictestsformycobacteriumtuberculosis